{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:26:55Z","timestamp":1794022015270,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA234787"],"award-info":[{"award-number":["R21CA234787"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA143970-05"],"award-info":[{"award-number":["U54CA143970-05"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.neo.2021.06.013","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T18:18:16Z","timestamp":1626805096000},"page":"851-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics"],"prefix":"10.1016","volume":"23","author":[{"given":"Renee","family":"Brady-Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Gatenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Enderling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2021.06.013_bib0001","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-020-15424-4","article-title":"Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation","volume":"11","author":"Brady-Nicholls","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.neo.2021.06.013_bib0002","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.neo.2021.06.013_bib0003","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ucl.2017.07.008","article-title":"Newly diagnosed metastatic prostate cancer: has the paradigm changed?","volume":"44","author":"Damodaran","year":"2017","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.neo.2021.06.013_bib0004","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.neo.2021.06.013_bib0005","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.neo.2021.06.013_bib0006","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cncr.21989","article-title":"Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters","volume":"107","author":"Bruchovsky","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.neo.2021.06.013_bib0007","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2021.06.013_bib0008","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2021.06.013_bib0009","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2021.06.013_bib0010","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2021.06.013_bib0011","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3","article-title":"LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer","volume":"35","author":"Fizazi","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2021.06.013_bib0012","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.neo.2021.06.013_bib0013","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.neo.2021.06.013_bib0014","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/app6110352","article-title":"Mathematical models of androgen resistance in prostate cancer patients under intermittent androgen suppression therapy","volume":"6","author":"Baez","year":"2016","journal-title":"Appl Sci"},{"key":"10.1016\/j.neo.2021.06.013_bib0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/pros.23099","article-title":"Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data","volume":"76","author":"Elishmereni","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.neo.2021.06.013_bib0016","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jtbi.2010.02.027","article-title":"Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer","volume":"264","author":"Hirata","year":"2010","journal-title":"J Theor Biol"},{"key":"10.1016\/j.neo.2021.06.013_bib0017","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00332-008-9031-0","article-title":"A mathematical model of intermittent androgen suppression for prostate cancer","volume":"18","author":"Ideta","year":"2008","journal-title":"J Nonlinear Sci"},{"key":"10.1016\/j.neo.2021.06.013_bib0018","doi-asserted-by":"crossref","first-page":"011002-1","DOI":"10.1063\/1.3697848","article-title":"A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy","volume":"2","author":"Portz","year":"2012","journal-title":"AIP Advances"},{"key":"10.1016\/j.neo.2021.06.013_bib0019","first-page":"1135","article-title":"Turnover modulates the need for a cost of resistance in adaptive therapy","author":"Strobl","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2021.06.013_bib0020","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1007\/s11538-019-00640-x","article-title":"Mathematical models of cancer: when to predict novel therapies, and when not to","author":"Brady","year":"2019","journal-title":"Bull Math Biol"},{"key":"10.1016\/j.neo.2021.06.013_bib0021","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free dna: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2021.06.013_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neo.2021.06.013_bib0023","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1038\/s41598-019-40719-y","article-title":"Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer","volume":"9","author":"Sumiyoshi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.neo.2021.06.013_bib0024","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","article-title":"Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer","volume":"2","author":"Wyatt","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.neo.2021.06.013_bib0025","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2011.35.8648","article-title":"End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2021.06.013_bib0026","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.molcel.2016.10.015","article-title":"Intercellular coupling of the cell cycle and circadian clock in adult stem cell culture","volume":"64","author":"Matsu-Ura","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.neo.2021.06.013_bib0027","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the tripod statement","volume":"162","author":"Collins","year":"2015","journal-title":"ann intern med"},{"key":"10.1016\/j.neo.2021.06.013_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228447","article-title":"Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study","volume":"15","author":"Thomsen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2021.06.013_bib0029","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.neo.2021.06.013_bib0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2021.06.013_bib0031","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neo.2021.06.013_bib0032","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neo.2021.06.013_bib0033","doi-asserted-by":"crossref","first-page":"E1648","DOI":"10.3390\/ijms18081648","article-title":"Targeting apoptotic activity against prostate cancer stem cells","volume":"18","author":"Jaworska","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neo.2021.06.013_bib0034","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1158\/1078-0432.CCR-09-3169","article-title":"Prostate stem cell antigen: a Jekyll and Hyde molecule?","volume":"16","author":"Saeki","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558621000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:09:26Z","timestamp":1761484166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558621000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1476558621000543"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2021.06.013","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2021.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}